Semaglutide Therapy Guidelines

Primary Indications for Semaglutide

The European Society of Cardiology recommends GLP-1 receptor agonists, including semaglutide, for patients with type 2 diabetes and chronic coronary syndromes to reduce cardiovascular events, independent of baseline or target HbA1c and independent of concomitant glucose-lowering medication 1.
Semaglutide reduces the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease 2.
The American Heart Association suggests that the cardiovascular benefits of semaglutide are preserved even in patients with chronic kidney disease, with greater MACE risk reduction observed in those with eGFR <60 mL/min/1.73 m² compared to those with higher eGFR 2.
The National Kidney Foundation recommends addition of a long-acting GLP-1 receptor agonist, such as semaglutide, for patients with type 2 diabetes and CKD not achieving individualized glycemic targets despite use of metformin and/or SGLT2 inhibitor therapy 2.
Semaglutide requires no dose adjustment for patients with renal impairment, including end-stage renal disease, making it advantageous over other diabetes medications 2.

The American Medical Association recommends semaglutide 2.4 mg weekly for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity 3.
In the STEP 1 trial, semaglutide achieved mean weight loss of 14.9% at 68 weeks compared to 2.4% with placebo (difference 12.4%; 95% CI, 11.5%-13.4%) 3.
The European Association for the Study of Obesity suggests that semaglutide 2.4 mg reduces the composite incidence of cardiovascular death, nonfatal MI, or nonfatal stroke (HR 0.80; 95% CI, 0.72-0.90) in patients with cardiovascular disease and BMI ≥27 without diabetes 3.

The European Society of Cardiology recommends considering semaglutide in overweight (BMI >27 kg/m²) or obese chronic coronary syndrome patients without diabetes to reduce cardiovascular mortality, MI, or stroke, representing a Class IIa recommendation with Level B evidence from the 2024 ESC guidelines 4, 1.

The American Diabetes Association recommends semaglutide for treatment in individuals with type 2 diabetes, obesity, and symptomatic HFpEF for reduction of heart failure-related symptoms, physical limitations, and exercise function 5.
In the STEP-HFpEF trial, semaglutide improved Kansas City Cardiomyopathy Questionnaire scores by 13.7 points versus 6.4 points with placebo and improved 6-minute walk distance 5.

The American Association for the Study of Liver Diseases suggests that a 72-week study in 320 patients with biopsy-proven NASH demonstrated that semaglutide 0.4 mg/day achieved NASH resolution without worsening fibrosis in 59% of patients versus 17% on placebo 6.
The study population included 62% with type 2 diabetes and >70% with moderate to advanced F2-3 liver fibrosis 6.

The American College of Cardiology recommends gradual dose titration of semaglutide to minimize gastrointestinal side effects 7.
For weight management, the target dose is 2.4 mg subcutaneously once weekly, achieved through gradual escalation 3.

The European Society of Cardiology notes that the most frequently reported adverse effects of semaglutide are gastrointestinal, including nausea, vomiting, diarrhea, and gastrointestinal reflux 7, 8.
Semaglutide is contraindicated in patients with a history of serious hypersensitivity reactions 8.
The American Heart Association suggests that semaglutide causes delayed gastric emptying, particularly during initial therapy 7.